首页 > 市场调查报告书 > 製药

神经疾病疼痛

市场调查报告书

商品编码

1608876

神经痛治疗药物市场：依药物类型、给药途径、严重程度、通路及地区分类

Neuralgia Treatment Market, By Drug Type (Anticonvulsants, Antidepressants, Opioids, Non-steroidal anti-inflammatory Drugs, and Others), By Route of Administration, By Severity, By Distribution Channel, By Geography

出版日期: 2024年11月20日 | 出版商:

Coherent Market Insights | 英文 172 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2024年全球神经痛治疗市场规模为24.1亿美元，2031年将达37.2亿美元，2024年至2031年复合年增长率为6.4%。

分析范围		分析详情
基准年	2023年	市场规模（2024年）	24.1亿美元
实际资料	2019-2023	预测期	2024-2031
预测期复合年增长率（2024-2031）	6.40%	预计金额（2031年）	37.2亿美元

图：2024年神经痛治疗药物市场占有率（%），依地区

神经痛，也称为神经病变疼痛，是由影响体感神经系统的损伤或疾病引起的慢性疼痛。它的特征是射击、刺伤或剧烈的疼痛，这种疼痛可能会被夸大或不可预测。常见的神经痛类型包括三叉神经痛、带状带状疱疹后遗症神经痛和纤维肌痛。近年来，由于神经病变疼痛疾病的盛行率不断上升以及易患此类疾病的老年人口数量不断增加，全球神经疼痛治疗市场出现了增长。此外，疗效提高且副作用最小的新药的开发也推动了对神经疼痛治疗的需求。

市场动态：

全球神经性疼痛药物市场是由神经病变疼痛疾病发病率不断上升以及世界老年人口不断增长所推动的。由于神经系统与老龄化相关的退化性变化，神经病变疼痛疾病在老年人中更为常见。此外，比传统治疗方法具有更高功效和更好安全性的新药的市场开拓正在推动市场成长。Carbamazepine和Gabapentin是常用于治疗神经疼痛的专利到期药物。然而，这些药物存在耐受性和依从性差的问题。因此，正在研究和开发具有改善的风险和益处的新治疗剂，例如钠通道阻断剂、NMDA受体拮抗剂和α2δ配体。另一方面，缓解疾病疗法的短缺和新疗法的高价格构成了挑战，在一定程度上限制了市场的扩张。然而，随着疼痛管理意识的提高和学名药的出现，未来几年将为神经疼痛治疗市场的参与者创造巨大的商机。

本研究的主要特点

该报告对全球神经痛治疗药物市场进行了详细分析，包括以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。做。

它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。

根据公司亮点、产品系列、主要亮点、绩效和策略等参数，提供全球神经痛治疗市场主要企业的概况。

研究涵盖的主要企业包括葛兰素史克(GlaxoSmithKline Plc PLC)、辉瑞公司(Pfizer Inc.)、诺华(Novartis AG)、百健(Biogen)、卡迪拉医疗保健有限公司(Cadila Healthcare Limited)、灵北製药(Lundbeck Pharmaceuticals LLC) 和梯瓦製药工业有限公司(Teva Pharmaceutical Industries Limited)、赛诺菲SA (Sanofi SA)、安进公司(Amgen Inc.)、礼来公司(Eli Lilly & Company)、安斯泰来製药(Astellas Pharma) 和强生公司 (Johnson)。还有A/S等。

该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。

全球神经疼痛治疗药物市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。

透过用于分析全球神经疼痛治疗药物市场的各种策略矩阵，将有助于相关人员做出决策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2024:	2.41 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	6.40%	2031 Value Projection:	3.72 Bn

Neuralgia, also known as neuropathic pain, is a chronic pain caused by damage or disease affecting the somatosensory nervous system. It is characterized by shooting, stabbing, and sharp pain that feels exaggerated or unpredictable. Some common types of neuralgia include trigeminal neuralgia, postherpetic neuralgia caused by shingles, and fibromyalgia. The global neuralgia treatment market has been witnessing growth in recent times owing to the rising prevalence of neuropathic pain disorders and growing geriatric population who are more prone to such conditions. Furthermore, the development of novel drugs providing improved efficacy and minimal side effects are also fueling the demand for neuralgia treatments.

Market Dynamics:

The global neuralgia treatment market is driven by the increasing incidence of neuropathic pain disorders coupled with the growing geriatric population globally. Neuropathic pain conditions are more prevalent in the elderly due to age-related degenerative changes in the nervous system. Additionally, the market growth is facilitated by the development of newer drugs offering enhanced efficacy and favorable safety profiles over conventional treatment options. Carbamazepine and gabapentin are off-patent drugs commonly used to treat neuralgia. However, their tolerability issues lead to poor compliance. This has triggered R&D of novel therapeutic classes like sodium channel blockers, NMDA receptor antagonists, and alpha-2 delta ligands that demonstrate improved risk-benefit ratios. On the other hand, lack of disease-modifying treatments and high cost of newer therapies are some challenges restraining the market expansion to a certain extent. Nevertheless, rise in awareness about pain management and availability of generic versions of branded drugs create huge opportunities for the neuralgia treatment market players in the coming years.

Key Features of the Study:

This report provides in-depth analysis of the global neuralgia treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global neuralgia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include GlaxoSmithKline PLC, Pfizer Inc., Novartis AG, Biogen, Cadila Healthcare Limited, Lundbeck Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Amgen Inc., Eli Lilly and Company, Astellas Pharma Inc., Johnson & Johnson, Merck & Co., Inc., AbbVie Inc., and H. Lundbeck A/S.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global neuralgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuralgia treatment market

Market Segmentation

Drug Type Insights (Revenue, USD Bn, 2019 - 2031)
- Anticonvulsants
- Antidepressants
- Opioids
- Non-steroidal anti-inflammatory Drugs (NSAIDs)
- Others
Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
- Oral
- Intravenous
- Transdermal
- Others
Severity Insights (Revenue, USD Bn, 2019 - 2031)
- Mild
- Moderate
- Severe
Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- GlaxoSmithKline PLC
- Pfizer Inc.
- Novartis AG
- Biogen
- Cadila Healthcare Limited
- Lundbeck Pharmaceuticals LLC
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Amgen Inc.
- Eli Lilly and Company
- Astellas Pharma Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- AbbVie Inc.
- Lundbeck A/S

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Neuralgia Treatment Market, By Drug Type
- Global Neuralgia Treatment Market, By Route of Administration
- Global Neuralgia Treatment Market, By Severity
- Global Neuralgia Treatment Market, By Distribution Channel
- Global Neuralgia Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Neuralgia Treatment Market, By Drug Type, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Opioids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Non-steroidal anti-inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Neuralgia Treatment Market, By Route of Administration, 2019-2031 (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Neuralgia Treatment Market, By Severity, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Mild
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Moderate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Severe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Neuralgia Treatment Market, By Distribution Channel, 2019-2031 (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Neuralgia Treatment Market, By Region, 2019 - 2031, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cadila Healthcare Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Lundbeck Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd.
Sanofi S.A.
Amgen Inc.
Eli Lilly and Company
Astellas Pharma Inc.
Johnson & Johnson
Merck & Co., Inc.
AbbVie Inc.
Lundbeck A/S

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

神经痛治疗药物市场：依药物类型、给药途径、严重程度、通路及地区分类